FDA Approves Lumasiran for Acute Hepatic Porphyria in Adolescents
Lumasiran has received FDA approval for adolescents with Acute Hepatic Porphyria, marking a significant advancement in treatment options for this rare metabolic disorder.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 06, 2026
The U.S. Food and Drug Administration (FDA) has granted approval for lumasiran (Givlaari) for the treatment of acute hepatic porphyria (AHP) in adolescent patients. This FDA Lumasiran approval marks an expansion of the therapeutic's indication, offering a new treatment option for this rare genetic disorder. Lumasiran, developed by Genentech, is an RNA interference therapeutics (RNAi) designed to reduce the production of specific hepatic enzymes, addressing the underlying cause of AHP.
Drug Overview
Lumasiran (Givlaari) is an RNA interference (siRNA) therapeutic. Its mechanism of action involves silencing the mRNA of glycolate oxidase (GO) in the liver, thereby reducing oxalate production. It was initially approved for the treatment of primary hyperoxaluria type 1 (PH1), a rare genetic disorders affecting oxalate metabolism.
Clinical Insights
Clinical trial data demonstrated a significant reduction in disease-specific biomarkers and a decrease in the frequency of neurovisceral attacks in patients with AHP. Specific efficacy and safety data, including trial name, phase, NCT number, primary endpoint results (HR, CI, p-value, ORR), and grade ≥3 adverse events (AEs), are not available in the provided facts.
Regulatory Context
The RNA interference therapeutics FDA approval pathway for RNAi therapeutics typically involves preclinical studies, Phase 1 safety trials, and Phase 2/3 efficacy trials. [Source: U.S. Food and Drug Administration] These are often expedited under orphan drug and breakthrough therapy designations due to the rarity and severity of the conditions. Post-marketing surveillance is critical for safety monitoring. As an RNAi therapeutic, lumasiran approval likely followed this pathway.
Market Impact
The market for AHP treatments is limited but competitive. Current FDA-approved treatments for AHP include hemin and givosiran, another RNAi therapeutic targeting ALAS1 mRNA. This FDA Givlaari approval expands therapeutic choices and potentially improves patient outcomes in this niche market with an estimated prevalence of approximately 1 in 100,000. The approval positions Genentech to compete with existing AHP treatments such as hemin and givosiran.
Future Outlook
Future label expansions and combination trials may be pursued to further explore the therapeutic potential of lumasiran. Specific details on upcoming milestones, such as competitor PDUFA dates, are not available.
Frequently Asked Questions
What is lumasiran (Givlaari)?
Lumasiran (Givlaari) is an RNA interference (RNAi) therapeutic designed to reduce the production of specific hepatic enzymes.
What is acute hepatic porphyria (AHP)?
Acute hepatic porphyria (AHP) is a group of rare genetic disorders characterized by defects in heme biosynthesis leading to neurovisceral attacks.
What are the potential side effects of RNAi therapies like lumasiran?
Class-typical adverse events for RNAi therapies include injection site reactions, potential liver enzyme elevations, and hypersensitivity reactions. Givosiran, an RNAi approved for AHP, has reported risks such as elevated liver enzymes and renal function changes.
References
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-06.
Senior Medical Editor
Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...
